Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.31 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708533 | 1.00 | MAP3K12 (0.38) | MAP3K12SYKMAPK14ATRPRKD1 | |
| SCHEMBL4094684 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL4089262 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL4089862 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL13708532 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL13708531 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL4089265 | 0.90 | MAPK14 (0.41) | MAP3K12MAPK14 | |
| SCHEMBL4090456 | 0.88 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL4091383 | 0.88 | MAPK14 (0.39) | MAP3K12SYKMAPK14ATRPRKD1 | |
| SCHEMBL4097400 | 0.87 | MAP4K2 (0.34) | MAP3K12SYKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | MAP3K12 397/4885SYK 240/4885MAPK14 1220/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | MAP3K12 285/4885SYK 189/4885MAPK14 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.